getpdf NLM PubMed Logo https://doi.org/10.17113/ftb.60.03.22.7456  

Fruit Extract Derived from a Mixture of Noni, Pineapple and Mango Capable of Coagulating Milk and Producing Curd with Antidiabetic Activities

Jaya Vejayan1*orcid tiny, Rupbansraaj Bathmanathan1orcid tiny, Sharifah Aminah Tuan Said1orcid tiny, Srikumar Chakravarthi2orcid tiny and Halijah Ibrahim3orcid tiny

1Faculty of Industrial Sciences & Technology, Universiti Malaysia Pahang, Lebuhraya Tun Razak, 26300, Gambang, Kuantan, Pahang Darul Makmur, Malaysia

2Faculty of Medicine, Biomedical Sciences and Nursing, MAHSA University, Jalan SP2, Bandar Saujana Putra, 42610 Jenjarom, Selangor, Malaysia

3Institute of Biological Sciences, University of Malaya, 50603 Kuala Lumpur, Malaysia

Article history:

Received: 2 August 2021

Accepted: 28 April 2022

cc by

Key words:

milk coagulation; antidiabetic curd; streptozotocin-induced diabetes; Morinda citrifolia; Mangifera indica; Ananas comosus

Summary:

Research background. Morinda citrifolia L. (noni), Ananas comosus L. cv. Sarawak (pineapple) and Mangifera indica L. cv. Apple (mango) represent fruits capable of coagulating milk, forming a curd. Plant-derived milk coagulants have antidiabetic phytochemicals that enrich the curd. Hence this work evaluated the dual benefits of the fruits in coagulating milk and the antidiabetic activities found in the curd produced by them.

Experimental approach. The three fruits were mixed to form a supercoagulant (a milk coagulant mixture of the extracts at a ratio of 1:1:1), and the milk coagulation time was measured. The milk was coagulated by the supercoagulant, and the fortified curd was tested for its ability to inhibit α-glucosidase and α-amylase. Then, the fortified curd was fed daily to streptozotocin-induced diabetic rats and compared with the untreated diabetic rats and normal rats related to their biochemical markers such as blood glucose level, aspartate aminotransferase, alanine transaminase etc. and histopathology of their liver and kidney tissues.

Results and conclusions. The supercoagulant had a milk coagulation time of (28±3) s at a 50 mg/mL concentration. Its fortified curd inhibited α-glucosidase and α-amylase, with IC50 values of (4.04±0.03) mg/mL and (3.42±0.02) mg/mL, respectively. The average mass of the streptozotocin-induced diabetic rats fed daily with curd formed by the supercoagulant (SC) was (201±10) g on day 20 in comparison to diabetic control rats (DC), (149±16) g. The blood glucose level after fasting for SC was (15±1) mmol/L compared to DC rats, (26±2) mmol/L. Blood tests on SC for aspartate aminotransferase, alanine transaminase, gamma-glutamyl transferase and alkaline phosphatase (liver function tests) levels were shown to be (214±78) U/L, (91±13) U/L, 3 U/L and (510±138) U/L, respectively, while the total protein test and renal function tests showed the levels of albumin, globulin, urea and creatinine to be (37±2) g/L, (30±2) g/L, (11±1) mmol/L and (42±3) µmol/L, respectively. These levels were found to be approximately similar to those of the normal rats on day 20. Furthermore, a histopathological study performed on the liver and kidney of the rats found no apparent damage.

Novelty and scientific contribution. This supercoagulant derived from a mixture of fruits is able to coagulate milk rapidly, and its curd is fortified with safe antidiabetic agents. The supercoagulant potentially useful in producing functional dairy food to prevent diabetes or as supplement for diabetics to control their blood sugar. Such products capable to replace dairy products derived from animal enzymes or add to existing functional dairy products for selection by consumers.

*Corresponding author: +6095492379
  +6095492766
  jayavejayan@ump.edu.my

Search FTB


Follow us


 facebook 1 twitter bird_icon LI In Bug

 

FTB RSS Feed


QR Code


qrcode

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our privacy policy.

I accept cookies from this site.

EU Cookie Directive Module Information